Database : MEDLINE
Search on : axilla [Words]
References found : 14610 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1461 go to page                         

  1 / 14610 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29505520
[Au] Autor:Liu H; Tao M; Ding H; Zhang P
[Ad] Address:Department of Ultrasonography.
[Ti] Title:Ultrasonographic manifestations of a rare granular cell tumor of the accessory breast: A case report.
[So] Source:Medicine (Baltimore);97(1):e9462, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: The ultrasound manifestations of granular cell tumor (GCT) is a consequence of the histopathological characteristic of the tumor and can be distinguished from breast cancer. PATIENT CONCERNS: A GCT is a rare, benign, hyperplasia-based lesion. Approximately 1% to 2% of GCTs are malignant. About 5% to15% of the cases occur in the breast, and it is relatively rare in the axillary accessory breast. There are no effective preventive measures for GCTs, early detection combined with a thorough and wide complete resection of the tumor remains the best treatment for a favorable outcome. DIAGNOSES: A 45-year-old female patient with an axillary mass of more than 3 months duration was examined through physical examination, color Doppler ultrasound and postoperative pathology. INTERVENTIONS: A provisional diagnosis of left axillary lymph node enlargement was made and necessary investigations were advised. OUTCOMES: A differential diagnosis of accessory breast in the left arm pit, possibly malignant, or a solid mass in the left arm pit secondary to chronic inflammation. Postoperative pathology: GCT of axillary accessory breast, with tumor-free margins. Immunohistochemical staining showed strong S-100 positivity, CD68 positivity, and negative periodic acid-Schiff staining. LESSONS: The ultrasound examination can detect GCT mass in the breast/accessory breast and is not easy to misdiagnosis.
[Mh] MeSH terms primary: Axilla/diagnostic imaging
Breast Neoplasms/diagnostic imaging
Granular Cell Tumor/diagnostic imaging
[Mh] MeSH terms secundary: Axilla/pathology
Breast Neoplasms/pathology
Female
Granular Cell Tumor/pathology
Humans
Middle Aged
Ultrasonography, Doppler, Color
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009462

  2 / 14610 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29519406
[Au] Autor:Schässburger KU; Paepke S; Saracco A; Azavedo E; Ekström C; Wiksell H
[Ad] Address:Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Electronic address: kai-uwe.schassburger@ki.se.
[Ti] Title:High velocity pulse biopsy device enables controllable and precise needle insertion and high yield tissue acquisition.
[So] Source:Phys Med;46:25-31, 2018 Feb.
[Is] ISSN:1724-191X
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:Minimally invasive biopsies are a cornerstone of breast cancer management with ultrasound being the preferred guidance modality. New developments in breast cancer management and advances in imaging technologies bring new challenges to current biopsy methodologies. A new biopsy device (NeoNavia® biopsy system, 14 G) was developed. It incorporates a pneumatic needle insertion mechanism that is intended to provide better control of needle progression and enable stepwise insertion without noticeable deformation or displacement of surrounding tissue as visualized under ultrasound. A new method of tissue acquisition was designed to achieve a sampling yield higher than standard methodologies. Needle dynamics was assessed on a specifically designed test bed and sampling performance was compared to a Magnum® biopsy instrument (Bard, Covington, GA, USA) in representative tissue models. The histological quality of samples obtained ex-vivo was evaluated. A pneumatic pulse was measured to accelerate the needle to a maximum velocity of 21.2 ±â€¯2.5 m/s on a stroke length of 2.5 mm, achieving significantly higher acceleration, maximum velocity and power than current biopsy devices. Mean weight of samples obtained by the NeoNavia device were 3.5, 4.6, and 4.3 times higher when sampling was performed in turkey breast, calf thymus and swine pancreas, respectively, as compared to samples obtained with the Magnum instrument. Ex-vivo analysis indicates that the method of tissue acquisition has no apparent negative impact on the histopathologic quality of obtained samples.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process

  3 / 14610 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29361075
[Au] Autor:Koehler LA; Hunter DW; Blaes AH; Haddad TC
[Ad] Address:Divisions of Physical Therapy and Rehabilitation Science, Department of Rehabilitation Medicine, University of Minnesota Medical School, Mayo Mail Code 388, 420 Delaware St. SE, Minneapolis, MN 55455; and Masonic Cancer Center, University of Minnesota.
[Ti] Title:Function, Shoulder Motion, Pain, and Lymphedema in Breast Cancer With and Without Axillary Web Syndrome: An 18-Month Follow-Up.
[So] Source:Phys Ther;, 2018 Jan 18.
[Is] ISSN:1538-6724
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Background: Axillary web syndrome (AWS) can develop following breast cancer surgery and presents as a tight band of tissue in the axilla with shoulder abduction. Objective: The objectives were to determine the prevalence and natural history of AWS, and the association between AWS and function, range of motion, pain, lymphedema, and body mass index (BMI). Design: This study was a longitudinal prospective cohort study utilizing a repeated measures design. Methods: Axillary web syndrome, function, shoulder range of motion, pain, and lymphedema (using circumference, bioimpedance spectroscopy, tissue dielectric constant) were assessed in women at 2, 4, and 12 weeks, and 18 months following breast cancer surgery. Prevalence of AWS and the association with the measured outcomes were analyzed. Results: Thirty-six women agreed to participate in the study. The cumulative prevalence of AWS was 50% (18/36) at 18 months following breast cancer surgery. AWS was identified as a risk factor for reduced function. Women with AWS had statistically reduced range of motion, lower BMI, and higher number of lymph nodes removed compared to the non-AWS group. Forty-one percent (13/32) of women had AWS at 18 months. AWS reoccurred in 6 women following resolution and a new case developed beyond the early postoperative period. The overall prevalence of physical impairments ranged from 66% to 97% within the first 18 months following surgery regardless of AWS. Limitations: Limitations include a small sample size and potential treatment effect. Conclusion: AWS occurs in approximately 50% of women following breast cancer surgery. It can persist for 18 months and potentially longer, develop beyond the early postoperative time period, and reoccur after resolution. Clinicians need to be aware of the chronicity of AWS and its association with reduced range of motion and function.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1093/ptj/pzy010

  4 / 14610 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29344685
[Au] Autor:Wang T; Dong J; He J
[Ad] Address:Department of Plastic and Reconstructive Surgery, Shanghai 9th People's Hospital, Shanghai JiaoTong University School of Medicine, 639 ZhiZaoJu Rd., Shanghai, 200011, People's Republic of China.
[Ti] Title:Long-Term Safety and Efficacy of Botulinum Toxin A Treatment in Adolescent Patients with Axillary Bromhidrosis.
[So] Source:Aesthetic Plast Surg;42(2):560-564, 2018 Apr.
[Is] ISSN:1432-5241
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: For adolescent bromhidrosis, the long-term safety and efficacy of botulinum toxin type A (BTX-A) treatment are not clear to date. PATIENTS AND METHODS: From June 2011 to July 2016, 62 adolescent patients with primary axillary bromhidrosis were recruited and 50 U of BTX-A was administered in each axilla. Repetitive injections were performed when the malodor returned. RESULTS: The average follow-up was 2.64 years. There were no reported local or systemic adverse effects. After the first BTX-A injection, 61.3% of patients (38/62) maintained the duration of more than 4 weeks. Of these patients, 21 patients underwent two sessions, 8 patients underwent three sessions, and 4 patients underwent four sessions. Twenty-four of sixty-two (38.7%) of patients had the duration of < 4 weeks. The second injection with the same dose was immediately administered, and the resulting duration increased to 9 weeks. Nineteen patients received the third injection with 100 U per underarm, and the resulting duration was extended up to 16 weeks. Overall, 82% of patients (51/62) ranked the BTX-A treatment to be very good or good. CONCLUSION: For adolescent axillary bromhidrosis, BTX-A injection is safe and effective over a long-term follow-up. The duration of efficacy is variable, and the dosage should be fine-tuned based on the individual response. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review
[do] DOI:10.1007/s00266-018-1075-4

  5 / 14610 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29242929
[Au] Autor:Morrow M
[Ad] Address:Memorial Sloan Kettering Cancer Center, New York, New York.
[Ti] Title:Management of the Node-Positive Axilla in Breast Cancer in 2017: Selecting the Right Option.
[So] Source:JAMA Oncol;4(2):250-251, 2018 Feb 01.
[Is] ISSN:2374-2445
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review
[do] DOI:10.1001/jamaoncol.2017.3625

  6 / 14610 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29506328
[Au] Autor:Park SH; Sim HB
[Ad] Address:Department of Plastic and Reconstructive Surgery, Soonchunhyang University Hospital, Seoul, Korea.
[Ti] Title:Endoscopic transaxillary prepectoral conversion for submuscular breast implants.
[So] Source:Arch Plast Surg;, 2018 Mar 05.
[Is] ISSN:2234-6163
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:Background: During breast augmentation, the transaxillary approach provides the advantage of allowing the mammary prosthesis to be placed through incisions that are remote from the breast itself, thereby reducing the visibility of postoperative scars. For patients experiencing capsular contracture who do not want additional scars, the previous transaxillary scar can be used for site change and implant exchange. Methods: This study analyzed 17 patients (34 breasts) with submuscular breast implants with grade III-IV capsular contracture who received treatment from 2010 to 2015. The mean age of the patients was 29 years (range, 20-38 years). The inclusion criterion was a pinch test of more than 3 cm at the upper pole of the breast. Previous axillary scars were used to expose the pectoralis fascia, and submuscular breast implants were removed carefully. The dissection underneath the pectoralis fascia was performed with endoscopic assistance, using electrocautery under direct visualization. Results: The mean follow-up period was 14 months (range, 6-24 months). The entire dissection plane was changed from the submuscular plane to the subfascial plane. Round textured gel implants were used, with a mean implant size of 220 mL (range, 160-300 mL). Two patients developed grade II capsular contracture. There were no cases of malposition or asymmetry. Three patients complained of minor implant palpability. None of the patients required additional surgery. Conclusions: Endoscopic subfascial conversion may be an effective technique for treating capsular contracture and avoiding scarring of the breast in selected patients.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:Publisher
[do] DOI:10.5999/aps.2017.01263

  7 / 14610 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29463144
[Au] Autor:Tanigasalam V; Vishnu Bhat B; Adhisivam B; Balachander B; Kumar H
[Ad] Address:a Department of Neonatology , Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER) , Pondicherry , India.
[Ti] Title:Hypothermia detection in low birth weight neonates using a novel bracelet device.
[So] Source:J Matern Fetal Neonatal Med;:1-4, 2018 Mar 04.
[Is] ISSN:1476-4954
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVE: The objective of this study is to assess the diagnostic accuracy of a novel hypothermia monitoring and alert bracelet device (BEMPU Bracelet) in low birth weight (LBW) neonates weighing less than 2000 g. DESIGN: This was a controlled prospective study. SETTING: This study was done in the step-down nursery of a tertiary level newborn unit of a major teaching hospital in India. METHODS: Eligible cases fulfilling inclusion criteria were given BEMPU Bracelets for a period of 24 h. A comparison was made between skin temperatures taken at the axilla by a mercury thermometer and skin temperatures taken at the wrist by the BEMPU Bracelet. Temperatures were taken every 6 h and every time the BEMPU Bracelet alarmed. Trained nurses obtained temperature measurements on newborns during their 24-h stay in the hospital step-down nursery. RESULTS: A total of 461 neonates were screened for hypothermia, giving 2428 temperature readings. Three hundred and eleven of 461 babies experienced hypothermia at some point. The 461 babies studied experienced 495 episodes of hypothermia in total. The sensitivity and the specificity of the bracelet in diagnosing hypothermia were 98.6% and 95% respectively. The positive and negative predictive values of the bracelet were 83.6% and 99.6%, respectively. The accuracy of the bracelet in diagnosing hypothermia was 95.8%. CONCLUSION: The BEMPU Bracelet is an accurate screening tool to detect and alert for neonatal hypothermia, thereby facilitating prompt management, which could prevent complications.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:Publisher
[do] DOI:10.1080/14767058.2018.1443072

  8 / 14610 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29246403
[Au] Autor:Qu LT; Peters S; Cobb AN; Godellas CV; Perez CB; Vaince FT
[Ad] Address:Loyola University Medical Center, Maywood, IL, United States.
[Ti] Title:Considerations for sentinel lymph node biopsy in breast cancer patients with biopsy proven axillary disease prior to neoadjuvant treatment.
[So] Source:Am J Surg;215(3):530-533, 2018 Mar.
[Is] ISSN:1879-1883
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Axillary disease can be downstaged with neoadjuvant treatment for breast cancer. We attempted to identify factors to consider in determining whether to perform a sentinel lymph node biopsy in patients with biopsy proven axillary metastases (cN+) prior to neoadjuvant treatment. METHODS: A retrospective chart review was conducted on patients at a single tertiary care center who underwent neoadjuvant treatment followed by surgery between 9/2013 and 2/2017. RESULTS: 47% of patients with node positive disease prior to neoadjuvant treatment were downstaged to node negative (ypN0) disease. These patients were more likely to have triple negative or Her2 positive disease than those patients who remained node positive (ypN+) as these were more likely to have hormone receptor positive disease. These patients were also more likely to demonstrate complete clinical imaging response of the primary tumor and axilla on preoperative breast MRI. CONCLUSIONS: Tumor biology and clinical response noted on breast MRI can help guide the decision to perform sentinel lymph node biopsy in patients with axillary node positive disease prior to neoadjuvant treatment.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:In-Data-Review

  9 / 14610 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29501020
[Au] Autor:Douskos A; Giannos A; Stavrou S; Sotiropoulou M; Feida E; Dimitrakakis C; Drakakis P; Rodolakis A
[Ad] Address:1(s,t)OB.GYN Department, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Lourou and Vasilissis Sofias Ave, 11528 Athens, Greece. Electronic address: thanosddoc@yahoo.gr.
[Ti] Title:A unique case of total metastatic lobular breast carcinoma, originating from diffused microcalcifications, presented in a postmenopausal woman, without clinical manifestations.
[So] Source:Int J Surg Case Rep;44:85-89, 2018 Feb 12.
[Is] ISSN:2210-2612
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Lobular breast carcinoma includes lobular carcinoma in situ (LCIS) and invasive lobular carcinoma (ILC). The association of LCIS with total metastatic lobular breast cancer is very rare. PRESENTATION OF CASE: We present a case of a totally metastatic lobular breast cancer in an asymptomatic 64-year-old postmenopausal woman, with no suspicious microcalcifications in mammography. A total hysterectomy with bilateral salpingo-oophorectomy, pelvic lymphadenectomy, infracolic omentectomy and appendectomy was performed along with a quadrantectomy of the upper outer quadrant of left breast, and systematic isolateral lymphadenectomy of the left axilla. DISCUSSION: LCIS is usually undetectable because it isn't associated with clinical abnormalities in clinical examination and is presented in mammography as microcalcifications or focal asymmetric densities. ILC histopathologic features are responsible for the high false-negative rates on mammography, leading to moderate detection sensitivity. CONCLUSION: Our case is a very rare condition. No 'similar' case have been described in the literature so far.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180303
[Lr] Last revision date:180303
[St] Status:Publisher

  10 / 14610 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29483583
[Au] Autor:Wu X; Tang P; Li S; Wang S; Liang Y; Zhong L; Ren L; Zhang T; Zhang Y
[Ad] Address:Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
[Ti] Title:A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.
[So] Source:Nat Commun;9(1):832, 2018 Feb 26.
[Is] ISSN:2041-1723
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180304
[Lr] Last revision date:180304
[St] Status:In-Data-Review
[do] DOI:10.1038/s41467-018-03210-2


page 1 of 1461 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information